Avanos Medical (AVNS) Cash & Equivalents (2013 - 2026)

Avanos Medical has disclosed Cash & Equivalents across 14 years of filings, most recently posting $65.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.37% year-over-year to $65.6 million; the TTM figure through Mar 2026 stood at $65.6 million (down 32.37% YoY), while the FY2025 annual figure was $89.8 million, down 16.62% from the prior year.
• Cash & Equivalents came in at $65.6 million for Q1 2026 at Avanos Medical, down from $89.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q4 2022 to a low of $65.6 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $94.5 million, with a median of $92.2 million recorded in 2024.
• Year-over-year, Cash & Equivalents climbed 27.97% in 2025 and slumped 32.37% in 2026.
• Over 5 years, Cash & Equivalents stood at $127.7 million in 2022, then slumped by 31.32% to $87.7 million in 2023, then grew by 22.81% to $107.7 million in 2024, then slipped by 16.62% to $89.8 million in 2025, then fell by 26.95% to $65.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $65.6 million in Q1 2026, $89.8 million in Q4 2025, and $70.5 million in Q3 2025.